SG10201913471VA - Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors - Google Patents

Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors

Info

Publication number
SG10201913471VA
SG10201913471VA SG10201913471VA SG10201913471VA SG10201913471VA SG 10201913471V A SG10201913471V A SG 10201913471VA SG 10201913471V A SG10201913471V A SG 10201913471VA SG 10201913471V A SG10201913471V A SG 10201913471VA SG 10201913471V A SG10201913471V A SG 10201913471VA
Authority
SG
Singapore
Prior art keywords
ehmt1
amine
substituted aryl
heteroaryl compounds
ehmt2 inhibitors
Prior art date
Application number
SG10201913471VA
Inventor
John Emmerson Campbell
Kenneth William Duncan
Megan Alene Foley
Darren Martin Harvey
Kevin Wayne Kuntz
James Edward John Mills
Michael John Munchhof
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of SG10201913471VA publication Critical patent/SG10201913471VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
SG10201913471VA 2016-04-15 2017-04-17 Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors SG10201913471VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662323602P 2016-04-15 2016-04-15
US201662348837P 2016-06-10 2016-06-10
US201662402997P 2016-09-30 2016-09-30

Publications (1)

Publication Number Publication Date
SG10201913471VA true SG10201913471VA (en) 2020-03-30

Family

ID=58664786

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201913471VA SG10201913471VA (en) 2016-04-15 2017-04-17 Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
SG11201808799SA SG11201808799SA (en) 2016-04-15 2017-04-17 Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201808799SA SG11201808799SA (en) 2016-04-15 2017-04-17 Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors

Country Status (24)

Country Link
US (2) US20170355712A1 (en)
EP (1) EP3442947B1 (en)
JP (3) JP7041070B2 (en)
KR (2) KR102571679B1 (en)
CN (1) CN109153650A (en)
AU (3) AU2017250369A1 (en)
BR (1) BR112018071093A2 (en)
CA (1) CA3021062A1 (en)
CL (2) CL2018002928A1 (en)
CO (1) CO2018012181A2 (en)
DK (1) DK3442947T3 (en)
ES (1) ES2953512T3 (en)
FI (1) FI3442947T3 (en)
HU (1) HUE064145T2 (en)
IL (3) IL281319B2 (en)
LT (1) LT3442947T (en)
MA (1) MA44666A (en)
MX (2) MX2018012622A (en)
PL (1) PL3442947T3 (en)
PT (1) PT3442947T (en)
SG (2) SG10201913471VA (en)
SI (1) SI3442947T1 (en)
TW (1) TWI751155B (en)
WO (1) WO2017181177A1 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6771023B2 (en) 2015-05-06 2020-10-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア K-RAS regulator
US10738035B2 (en) 2015-05-13 2020-08-11 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
KR102398439B1 (en) 2016-03-07 2022-05-16 이난타 파마슈티칼스, 인코포레이티드 Hepatitis B antiviral drugs
UA124764C2 (en) 2016-04-15 2021-11-17 Еббві Інк. Bromodomain inhibitors
WO2017201199A1 (en) 2016-05-17 2017-11-23 Duke University Compositions and methods for the treatment of prader-willi syndrome
KR20190092542A (en) * 2016-12-19 2019-08-07 에피자임, 인코포레이티드 Amine-Substituted Heterocyclic Compounds as EHMT2 Inhibitors and Methods of Use thereof
EP3600318A4 (en) * 2017-03-31 2021-06-09 Epizyme, Inc. Methods of using ehmt2 inhibitors
CN110785414A (en) * 2017-04-20 2020-02-11 加利福尼亚大学董事会 K-Ras modulators
CA3060416A1 (en) * 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
TWI811236B (en) 2017-08-28 2023-08-11 美商因那塔製藥公司 Hepatitis b antiviral agents
CN109467538A (en) 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 The heteroaryl cyclics and application thereof that cycloolefin replaces
EP3697419A4 (en) * 2017-10-17 2021-08-18 Epizyme, Inc. Amine-substituted heterocyclic compounds as ehmt2 inhibitors and derivatives thereof
IL301746A (en) * 2017-10-18 2023-05-01 Epizyme Inc Amine-substituted heterocyclic compounds as ehmt2 inhibitors, salts thereof, and methods of synthesis thereof
IL273824B1 (en) * 2017-10-18 2024-03-01 Epizyme Inc Methods of using ehmt2 inhibitors in treating or preventing blood disorders
EA202090955A1 (en) * 2017-10-18 2020-11-27 Эпизайм, Инк. METHODS OF USING EHMT2 INHIBITORS IN TREATMENT OR PREVENTION OF BLOOD DISORDERS
WO2019143902A2 (en) 2018-01-22 2019-07-25 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
SG11202007754UA (en) 2018-02-15 2020-09-29 Nuvation Bio Inc Heterocyclic compounds as kinase inhibitors
CN108822103A (en) * 2018-07-28 2018-11-16 刘凤娟 A kind of imidazo [4,5-b] pyridine compounds and its preparation method and application
BR112021005091A2 (en) 2018-09-21 2021-06-08 Enanta Pharmaceuticals, Inc. heterocycles functionalized as antiviral agents
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
TWI721624B (en) 2018-10-31 2021-03-11 美商基利科學股份有限公司 Substituted 6-azabenzimidazole compounds
CN113227089A (en) 2018-10-31 2021-08-06 吉利德科学公司 Substituted 6-azabenzimidazole compounds as HPK1 inhibitors
UY38483A (en) 2018-11-21 2020-06-30 Enanta Pharm Inc HETEROCYCLES FUNCTIONALIZED AS ANTIVIRAL AGENTS
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020224568A1 (en) * 2019-05-05 2020-11-12 Qilu Regor Therapeutics Inc. Cdk inhibitors
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
US11236111B2 (en) 2019-06-03 2022-02-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2020247561A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
US11472808B2 (en) 2019-06-04 2022-10-18 Enanta Pharmaceuticals, Inc. Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
WO2021007488A1 (en) 2019-07-11 2021-01-14 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
GB201910608D0 (en) * 2019-07-24 2019-09-04 Enterprise Therapeutics Ltd Compounds
KR20220064369A (en) 2019-08-14 2022-05-18 인사이트 코포레이션 Imidazolyl Pyridimidinylamine Compounds as CDK2 Inhibitors
US11236108B2 (en) 2019-09-17 2022-02-01 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
CR20220170A (en) 2019-10-11 2022-10-10 Incyte Corp Bicyclic amines as cdk2 inhibitors
EP4066896A4 (en) * 2019-11-27 2024-03-27 Riken G9a inhibitor
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
CA3182541A1 (en) 2020-05-04 2021-11-11 Amgen Inc. Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
TW202208355A (en) 2020-05-04 2022-03-01 美商安進公司 Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
CN111518015A (en) * 2020-05-20 2020-08-11 上海合全药物研发有限公司 Preparation method of tert-butyl-8-oxylidene-2-azaspiro [4.5] decane-2-formic acid ester
JP2024508794A (en) 2021-02-19 2024-02-28 スドー バイオサイエンシーズ リミテッド TYK2 inhibitors and their uses
WO2023064586A1 (en) * 2021-10-15 2023-04-20 Tango Therapeutics, Inc. Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof
WO2024019541A1 (en) * 2022-07-20 2024-01-25 일동제약(주) Heteroaryl derivative compound and use thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0585500A1 (en) * 1992-09-04 1994-03-09 Merrell Dow Pharmaceuticals Inc. Diaryl piperazineacetamides as antimuscarinic agents
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
JP4510442B2 (en) * 2001-06-26 2010-07-21 ブリストル−マイヤーズ スクイブ カンパニー N-heterocyclic inhibitor of TNF-α expression
EP1453516A2 (en) * 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG Novel tri-substituted pyrimidines, method for production and use thereof as medicament
NZ537752A (en) * 2002-07-29 2006-12-22 Rigel Pharmaceuticals Inc Use of 2,4-pyrimidinediamine compounds in the preparation of medicaments for treating autoimmune diseases
US20070105839A1 (en) * 2003-09-18 2007-05-10 Patricia Imbach 2, 4-Di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
JP2008505907A (en) * 2004-07-06 2008-02-28 アンジオン バイオメディカ コーポレイション Quinazoline modulators that modulate hepatocyte growth factor and c-met activity for cancer therapy
JP5483874B2 (en) * 2005-05-05 2014-05-07 サノフィ−アベンティス・ユー・エス・エルエルシー Stable nanoparticle formulation
EP1746096A1 (en) * 2005-07-15 2007-01-24 4Sc Ag 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
JP2009501164A (en) * 2005-07-15 2009-01-15 ４エスツェー アクチェンゲゼルシャフト 2-Arylbenzothiazole and use thereof
WO2007038387A2 (en) * 2005-09-23 2007-04-05 Yale University Compounds and methods for the treatment of viruses and cancer
AU2006309013B2 (en) * 2005-11-01 2012-06-28 Impact Biomedicines, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
TW200736232A (en) * 2006-01-26 2007-10-01 Astrazeneca Ab Pyrimidine derivatives
CA2647592C (en) * 2006-05-26 2014-01-28 Abbott Laboratories Inhibitors of polo-like kinases
RU2010137300A (en) * 2008-02-22 2012-03-27 Ф. Хоффманн-Ля Рош Аг (Ch) BETA AMYLOID MODULATORS
KR20100132550A (en) * 2008-04-16 2010-12-17 포톨라 파마슈티컬스, 인코포레이티드 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors
MX2011001426A (en) * 2008-08-05 2011-03-21 Targegen Inc Methods of treating thalassemia.
US20110230478A1 (en) * 2008-09-03 2011-09-22 Bayer ScienceCrop AG 4-Alkyl-substituted diaminopyrimidines
US8367689B2 (en) * 2009-05-06 2013-02-05 Portola Pharmaceuticals, Inc. Inhibitors of JAK
JP5713367B2 (en) * 2010-06-04 2015-05-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Aminopyrimidine derivatives as LRRK2 modulators
WO2012044936A1 (en) * 2010-09-30 2012-04-05 Portola Pharmaceuticals, Inc. Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide
KR101682417B1 (en) * 2011-02-25 2016-12-06 주식회사유한양행 Diaminopyrimidine derivatives and processes for the preparation thereof
WO2013054351A1 (en) * 2011-08-08 2013-04-18 Cadila Healthcare Limited Heterocyclic compounds
WO2013033037A2 (en) * 2011-08-26 2013-03-07 The Regents Of The University Of California Novel antiprion compounds
WO2013070852A2 (en) * 2011-11-08 2013-05-16 Emory University Compounds and compositions used to epigenetically transform cells and methods related thereto
KR101452235B1 (en) * 2012-02-03 2014-10-22 서울대학교산학협력단 Novel pyrimidine derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition for prevention or treatment of RAGE receptor related diseases containing the same as an active ingredient
ES2872348T3 (en) * 2012-03-19 2021-11-02 Imperial College Innovations Ltd Quinazoline compounds and their use in therapy
GB201209613D0 (en) * 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
EP2903970A4 (en) * 2012-10-08 2016-11-30 Portola Pharm Inc Substituted pyrimidinyl kinase inhibitors
US9145412B2 (en) * 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
WO2015109109A1 (en) * 2014-01-15 2015-07-23 Forum Pharmaceuticals Inc. Fused morpholinopyrimidines and methods of use thereof
AU2015276537B2 (en) * 2014-06-16 2019-03-14 Fundacion Para La Investigacion Medica Aplicada Novel compounds as dual inhibitors of histone methyltransferases and dna methyltransferases

Also Published As

Publication number Publication date
CL2019000815A1 (en) 2019-08-16
CL2018002928A1 (en) 2019-02-01
KR20230130747A (en) 2023-09-12
DK3442947T3 (en) 2023-09-04
ES2953512T3 (en) 2023-11-14
IL281319A (en) 2021-04-29
MX2018012622A (en) 2019-08-29
US20170355712A1 (en) 2017-12-14
EP3442947A1 (en) 2019-02-20
CN109153650A (en) 2019-01-04
KR20180133906A (en) 2018-12-17
JP2024045202A (en) 2024-04-02
US20210198277A1 (en) 2021-07-01
IL281319B1 (en) 2023-11-01
TWI751155B (en) 2022-01-01
SI3442947T1 (en) 2023-10-30
IL281319B2 (en) 2024-03-01
IL307931A (en) 2023-12-01
WO2017181177A1 (en) 2017-10-19
FI3442947T3 (en) 2023-08-24
HUE064145T2 (en) 2024-03-28
AU2017250369A1 (en) 2018-10-11
BR112018071093A2 (en) 2019-01-29
JP7041070B2 (en) 2022-03-23
PT3442947T (en) 2023-08-07
IL262140A (en) 2018-11-29
AU2024200464A1 (en) 2024-02-15
AU2021245168A1 (en) 2021-11-04
KR102571679B1 (en) 2023-08-29
AU2021245168B2 (en) 2023-10-26
EP3442947B1 (en) 2023-06-07
MA44666A (en) 2019-02-20
CO2018012181A2 (en) 2019-08-20
SG11201808799SA (en) 2018-11-29
JP2019513778A (en) 2019-05-30
LT3442947T (en) 2023-09-11
TW201803854A (en) 2018-02-01
PL3442947T3 (en) 2023-10-02
JP7420847B2 (en) 2024-01-23
MX2022010947A (en) 2022-09-21
CA3021062A1 (en) 2017-10-19
JP2022081606A (en) 2022-05-31

Similar Documents

Publication Publication Date Title
IL281319A (en) Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
HRP20190506T1 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
ZA201702402B (en) Heteroaryl compounds as irak inhibitors and uses thereof
ZA201801056B (en) Heteroaryl compounds as irak inhibitors and uses thereof
ZA201701501B (en) Heteroaryl compounds as btk inhibitors and uses thereof
ZA201800975B (en) Heteroaryl compounds as irak inhibitors and uses thereof
IL267090A (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
IL257448A (en) Bicyclic-fused heteroaryl or aryl compounds
HK1231484A1 (en) Amido-substituted azole compounds as inhibitors of tnks1 and/or tnks2 tnks1 / tnks2